| Prev Close | 21.96 |
| Day Low/High | 21.44 / 22.29 |
| 52 Wk Low/High | 13.67 / 27.80 |
Exelixis, Inc. (EXEL)
21.66
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 311.99B |
| Market Cap | 6.85B |
| P/E Ratio | 46.12 |
| Div & Yield | N.A. (N.A) |
Two Oncology Stocks I Like Now
M&A activity should pick up in the biotech space.
Which Hot Biotech Name Will Be Acquired Next?
Your burning biotech questions answered in our latest mailbag.
Bret Jensen's Biotech Mailbag
We'll answer two of the common questions we have received so far in March.
Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers
The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.
Exelixis Has an Enviable Chart Pattern
The $30 area is probably up next.
Fewer Oars Make Market Tough Row to Hoe
Investors should be more cautious heading into the summer.
These Stocks Are Changing Direction
Finding bullish and bearish reversals in the market.
Biotech Heating up on M&A Speculation
The market is pretty close to where it was during our last update at noon EST. So far it has been a nicely green day across the board. Oncology mid-cap concern Tesaro is not giving up its big takeover speculation rise yesterday and is up another 3%...
Hopes for Tax Reform, Less Regulation Lift Indices
Technical indicators indicate the markets are not extended and have consolidated nicely.
The Next Target in Biotech Land
The Actelion buyout opens the way for other deals.
The Next Target in Biotech Land
The Actelion buyout opens the way for other deals.
4 Biotech Names That Could Be M&A Targets
Animal health and oncology deal activity is heating up in 2017.
Look at Silver Miners and Some Names That Have Pulled Back
I'm feeling pressure to force some trades today, but I'm trying to stay selective.
Shark Bites: Eager Buyers Pounce on Pullback
I'm underinvested, which isn't good when indices are up.
How to Be a Smarter Biotech Investor
Interpreting "K-M curves" correctly is an important tool for biotech investors.
3 Biotech-Investing Mistakes to Avoid
These are the biggest errors that I've made over the years.
Don't Roll the Dice on Central Bank News
The bears are trying it out on the Bank of England news today, but they may get squeezed.
'Sell the News' Reaction Is Quite Logical
After poor close on Thursday, market trends down all day.
Sneaky Market Strength Has Nothing to Do With the Fed
Anxiety over being left behind is building.
Yawning All the Way to the Fed Decision
We have a few more days of this slow trading, and it is unlikely to change much.
Late Dip Doesn't Dent Market's V-Shaped Rally
But how much more upside can there be?
Market Momentum, Such as It Is, Peters Out
Stocks retreat to a trading range.
Market Wrap: A Tech-Led Tick Higher
But energy and materials names, crude oil and gold all dropped.
Where the Money Was Made the Last 5 Years
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
Earnings Roundup
Here is my compilation of last night's profit reports. 24 beats: W&T Offshore (WTI) Oasis Petroleum (OAS) Marathon Oil (MRO) Huntington Ingalls Industries (HII) Cognizant Technology Solutions (CTSH) Disney (DIS) Electronic Arts (EA) Regency Centers ...
Stocks Under $5: Blossoming Biotech Play
Portfolio manager David Peltier discusses how to play one the most volatile low-dollar stocks of 2012.
